Literature DB >> 26443306

Retrospective analysis of 95 patients with large vessel vasculitis: a single center experience.

Masaaki Yoshida1, Ryu Watanabe1, Tomonori Ishii1, Tomoaki Machiyama1, Kanae Akita1, Yoko Fujita1, Yuko Shirota1, Koichiro Sugimura2, Hiroshi Fujii1, Hiroaki Shimokawa2, Hideo Harigae1.   

Abstract

AIM: Although Takayasu arteritis (TAK) and giant cell arteritis (GCA) have been considered as distinct disease entities, similarities of these diseases have been recently reported. However, little data is available regarding this issue in Japanese patients with TAK and GCA. In addition, the classification criteria for TAK established in 1990 by the American College of Rheumatology (ACR) have been criticized due to the age restriction for disease onset (≤ 40 years). Thus, we aimed to compare the clinical characteristics of Japanese patients with TAK and those with GCA and to clarify whether clinical differences existed between patients with early-onset (≤ 40 years) and late-onset (> 40 years) TAK.
METHODS: We enrolled 86 patients with TAK and nine with GCA who visited our department from 1990 to 2014. The diagnoses of TAK and GCA were based on the criteria of the Japanese Circulation Society and the ACR, respectively.
RESULTS: Mean ages at onset for TAK and GCA were 36.4 and 71.0 years, respectively. Patients with TAK had significantly higher incidences of aortic regurgitation and carotid and subclavian arterial involvement, lower frequencies of polymyalgia rheumatica, and better prognoses than those with GCA. In contrast, the clinical characteristics, distribution of arterial lesions, treatments administered, and prognoses of patients with early- and late-onset TAK were comparable.
CONCLUSIONS: These results suggested that TAK and GCA differed substantially, and that the age restriction (≤ 40 years) may not be necessary for the diagnosis of TAK.
© 2015 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  Takayasu arteritis; giant cell arteritis; large vessel vasculitis

Mesh:

Substances:

Year:  2015        PMID: 26443306     DOI: 10.1111/1756-185X.12777

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  7 in total

1.  Cytokines, growth factors and proteases in medium and large vessel vasculitis.

Authors:  Cornelia M Weyand; Ryu Watanabe; Hui Zhang; Mitsuhiro Akiyama; Gerald J Berry; Jörg J Goronzy
Journal:  Clin Immunol       Date:  2019-02-14       Impact factor: 3.969

2.  Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasu's arteritis.

Authors:  Ying Sun; Lili Ma; Lingying Ma; Xiufang Kong; Huiyong Chen; Peng Lv; Jiang Lin; Hao Liu; Yan Yan; Zongfei Ji; Chengde Yang; Shengming Dai; Weiguo Wan; Yaohong Zou; Xuejuan Jin; Lindi Jiang
Journal:  Rheumatol Int       Date:  2017-10-13       Impact factor: 2.631

Review 3.  Vasculitogenic T Cells in Large Vessel Vasculitis.

Authors:  Ryu Watanabe; Motomu Hashimoto
Journal:  Front Immunol       Date:  2022-06-15       Impact factor: 8.786

Review 4.  Physical Exercise in Managing Takayasu Arteritis Patients Complicated With Cardiovascular Diseases.

Authors:  Yaxin Zhou; Yuan Feng; Wei Zhang; Hongxia Li; Kui Zhang; Zhenbiao Wu
Journal:  Front Cardiovasc Med       Date:  2021-05-12

Review 5.  Cellular Signaling Pathways in Medium and Large Vessel Vasculitis.

Authors:  Ryu Watanabe; Gerald J Berry; David H Liang; Jörg J Goronzy; Cornelia M Weyand
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561

6.  Risk factors of aortic regurgitation progression in Chinese patients with Takayasu's arteritis: a prospective cohort study.

Authors:  Yujiao Wang; Lili Ma; Ying Sun; Wensu Yu; Sifan Wu; Huiyong Chen; Xiaomin Dai; Lingying Ma; Lindi Jiang
Journal:  Ther Adv Chronic Dis       Date:  2022-10-05       Impact factor: 4.970

Review 7.  Pathogenesis of Giant Cell Arteritis and Takayasu Arteritis-Similarities and Differences.

Authors:  Ryu Watanabe; Gerald J Berry; David H Liang; Jörg J Goronzy; Cornelia M Weyand
Journal:  Curr Rheumatol Rep       Date:  2020-08-26       Impact factor: 4.686

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.